文献速递胸部肿瘤乳腺癌

Aurora A激酶抑制与RB1抑癌基因缺失合成致死

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.
PubMed 文献 · Cancer Discov · 2018-10-29

RB1功能缺失突变常见于小细胞肺癌和三阴性乳腺癌等难治性肿瘤。研究者用优化的癌细胞panel筛选36种细胞周期抑制剂,发现AURKA/AURKB抑制剂与RB1突变关联最强。高选择性AURKA抑制剂LY3295668对RB1突变癌细胞有活性浓度下对骨髓细胞毒性极小,并在耐受暴露下使RB1突变肿瘤异种移植持久退缩。遗传抑制筛选提示纺锤体组装检查点(SAC)是LY3295668在RB1缺陷癌中细胞毒性的关键。

要点

  • RB1缺失肿瘤对AURKA抑制敏感,呈合成致死。
  • LY3295668对AURKA选择性较AURKB高逾1000倍。
  • LY3295668在活性浓度下对骨髓细胞毒性极小。

核心结论

  • RB1缺失与AURKA抑制存在合成致死相互作用。
  • LY3295668可连续给药实现AURKA持续抑制而不引起骨髓抑制,为RB1缺陷恶性肿瘤提供新治疗思路。

研究设计与样本

  • 用优化的癌细胞panel筛选36种细胞周期抑制剂以区分细胞毒与细胞静止效应。
  • 采用遗传抑制筛选鉴定LY3295668在RB1缺陷癌中细胞毒性的关键通路。
  • 使用RB1突变肿瘤异种移植模型评估LY3295668的体内疗效与耐受性。

主要发现

  • 36种细胞周期抑制剂筛选中AURKA和AURKB抑制剂与RB1关联最强。
  • LY3295668对AURKA选择性较AURKB高逾1000倍。
  • LY3295668在活性浓度下对骨髓细胞毒性极小。
  • LY3295668在啮齿类耐受暴露下使RB1突变肿瘤异种移植持久退缩。
  • SAC增强因子是LY3295668在RB1缺陷癌中细胞毒性的必需因素。

临床怎么用

  • RB1缺失的小细胞肺癌和三阴性乳腺癌等难治肿瘤可考虑AURKA抑制策略。
  • LY3295668因骨髓毒性小,支持连续给药以持续抑制AURKA。
  • 该策略可能适用于CDK4/6抑制剂进展后的RB1缺陷肿瘤患者。

局限性

  • 主要证据来自临床前细胞panel和异种移植模型,尚未报告人体试验数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Loss-of-function mutations in the retinoblastoma gene RB1 are common in several treatment-refractory cancers such as small-cell lung cancer and triple-negative breast cancer. To identify drugs synthetic lethal with RB1 mutation (RB1 mut), we tested 36 cell-cycle inhibitors using a cancer cell panel profiling approach optimized to discern cytotoxic from cytostatic effects. Inhibitors of the Aurora kinases AURKA and AURKB showed the strongest RB1 association in this assay. LY3295668, an AURKA inhibitor with over 1,000-fold selectivity versus AURKB, is distinguished by minimal toxicity to bone marrow cells at concentrations active against RB1 mut cancer cells and leads to durable regression of RB1 mut tumor xenografts at exposures that are well tolerated in rodents. Genetic suppression screens identified enforcers of the spindle-assembly checkpoint (SAC) as essential for LY3295668 cytotoxicity in RB1-deficient cancers and suggest a model in which a primed SAC creates a unique dependency on AURKA for mitotic exit and survival. SIGNIFICANCE: The identification of a synthetic lethal interaction between RB1 and AURKA inhibition, and the discovery of a drug that can be dosed continuously to achieve uninterrupted inhibition of AURKA kinase activity without myelosuppression, suggest a new approach for the treatment of RB1-deficient malignancies, including patients progressing on CDK4/6 inhibitors.See related commentary by Dick and Li, p. 169.This article is highlighted in the In This Issue feature, p. 151.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Gong X, Du J, Parsons SH, et al. Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene. Cancer Discov. 2018. PMID: 30373917. doi:10.1158/2159-8290.CD-18-0469

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。